Publications

2023

Van Emmenis L, Ku S-, Gayvert K, Branch JR, Brady NJ, Basu S, et al. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer Res Commun. 2023;3(8):1447-1459.
Helfgott DC, Racine-Brzostek S, Short KJ, Zhao Z, Christos P, Nino I, et al. Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2023;64(3):662-670.

2022

Choi SY, Ribeiro CF, Wang Y, Loda M, Plymate SR, Uo T. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules. 2022;12(11).
Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, et al. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022;6:e2200329.
Hissong E, Mowers J, Zhao L, Greenson JK, Bachman M, Lamps LW. Histologic and Clinical Correlates of Multiplex Stool Polymerase Chain Reaction Assay Results. Arch Pathol Lab Med. 2022;146(12):1479-1485.
Sun J, Greenblatt MB. To the bones: mapping the skeletal LEPR+ pool to component cell types. EMBO J. 2022;41(4):e110343.
Elhadad S, Chadburn A, Magro C, Van Besien K, Roberson ED, Atkinson JP, et al. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy. Bone Marrow Transplant. 2022;57(9):1445-1447.
Velu P, Cong L, Rand S, Qiu Y, Zhang Z, Zhang J, et al. Rapid detection of SARS-CoV-2 variants of concern by single nucleotide polymorphism genotyping using TaqMan assays. Diagn Microbiol Infect Dis. 2022;104(4):115789.
Boyraz B, Watkins JC, Soubeyran I, Bonhomme B, Croce S, Oliva E, et al. Cystic Granulosa Cell Tumors of the Ovary: An Analysis of 80 Cases of an Often Diagnostically Challenging Entity. Arch Pathol Lab Med. 2022;146(12):1450-1459.
Buyukozkan M, Alvarez-Mulett S, Racanelli AC, Schmidt F, Batra R, Hoffman KL, et al. Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. iScience. 2022;25(7):104612.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700